EN DE
Watch BGI Genomics Co Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

BGI Genomics Co Ltd (300676) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of BGI Genomics Co Ltd stock ¥20.06, price ¥38.39, that is 47.7% below the price, quality 48 out of 100. Rating: strongly overvalued. Calculated from audited financials with 2 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE100003449

BG BGI Genomics Co Ltd logo Thin data Nov 7, 2026

BGI Genomics Co Ltd

300676 · SHE
Very expensive, weak quality

Our calculation puts a fair price 48% below what the stock costs today.

Low debt
Quality 48/100
Revenue last quarter 13% below a year ago.
Fair value ¥20.06 · Strongly overvalued
Weak Growth (revenue 5y −15.1 %/yr in CNY)
Loss-making · -14.6% net margin (TTM)
Negative free cash flow
Trails peers (2/11)
Narrow moat 13/100
Thin data
Watch BGI Genomics Co Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥125.11 ¥32.88 Fair Value ¥20.06 May 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

60‑month range ¥32.88 – ¥125.11 · fair‑value band ¥17.15 – ¥22.97 · the ¥38.39 price screens above the ¥20.06 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.

Follow BGI Genomics Co in your weekly email

Every Wednesday you see whether BGI Genomics Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

BGI Genomics Co., Ltd. engages in the provision of research services, comprehensive precision medicine testing solutions, and health management services in China and internationally.

Show moreShow less

The company offers DNA sequencing services comprising plant/animal/microbial whole genome re-sequencing and de novo sequencing; human whole genome sequencing, long-read human whole genome resequencing, and whole exome sequencing; epigenetics whole genome bisulfite sequencing and ChIp-Seq; and metagenomics and 16S/18S/ITS sequencing.

It also provides RNA sequencing, long non-coding RNA sequencing, small RNA sequencing, iso-seq / pacbio transcriptome sequencing; single cell sequencing and high throughput single cell RNA-Seq; spatial transcriptome-stereo-seq; immune repertoire and pre-made library sequencing; and bioinformatics solutions.

In addition, the company offers mass spectrometry, including proteomics, metabolomics, and multi-omics. Further, it provides clinical solutions for reproductive health, oncology, infectious disease, and chronic disease.

The company was formerly known as Shenzhen BGI Medicine Co., Ltd. and changed its name to BGI Genomics Co., Ltd. in 2015. The company was founded in 1999 and is headquartered in Shenzhen, China. BGI Genomics Co., Ltd. operates as a subsidiary of BGI Group.

Stock analysis

BGI Genomics Co Ltd (300676) currently trades at ¥38.39, while our model-based Fair Value estimate is ¥20.06, 48% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 93/100, which puts the data coverage at low.

Scenario range: ¥17.15 (bear) to ¥22.97 (bull), the price of ¥38.39 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

BGI Genomics Co Ltd reported revenue of 3.7B CNY in FY2025 versus 6.8B CNY in FY2021, a compound −14.0%/yr. Reported net income was −617M CNY in FY2025.

Key figures

Market cap 16.1B CNY (≈ $2.4B) Mid · P/S ratio 4.55 · EPS (TTM) ¥−1.38 · Dividend yield 0.1% · Net margin −14.6% · Return on equity −6.3% · Return on assets (EBIT) 2.6% (5-year average) · Operating margin 3.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 13 out of 100 (medium confidence).

What moves the price

The share trades about 35% below its 52-week high and 17% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at −48%, 300676 screens richer than that median.

Fair Value models

Bear ¥17.15 Fair Value ¥20.06 Bull ¥22.97
Price ¥38.39 · Downside -47.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EV/EBITDA ¥17.15 ¥20.06 ¥22.97 67
NCAV (Graham) ¥4.57 ¥6.92 ¥8.65 54
All 2 models by family
Multiples
EV/EBITDA ¥17.15 ¥20.06 ¥22.97 67
Asset-Based
NCAV (Graham) ¥4.57 ¥6.92 ¥8.65 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 48/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 7
How much profit the company makes from its sales and capital
Quality Growth 53
Are margins and returns getting better?
Cashflow 3
Do the profits arrive as real cash?
Financial strength 98
Debt, balance sheet and risk of trouble
Investment 78
Does it invest with discipline instead of growing at any price?
Low Volatility 62
How calm the share price moves, does not count
Price momentum 36
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 16
Distance to the 52-week high, does not count
New shares 71
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−4.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−19.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−15.1%
Start year 2020 (pandemic). Over 10 years: +10.9% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
29.7% (2020) → −4.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

300676 screens overvalued: fair value 48% below the price. Compare with Thermo Fisher Scientific Inc →

Compare BGI Genomics Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks

Beats the industry median on 2/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 48 · Below median
Fair Value upside −47.7% · Below median
Profitability
Return on assets −5.3% · Below median
Net margin (12 months) −14.6% · Bottom 25%
Operating margin (12 months) 3.7% · Below median
Growth and dividend
Revenue growth (quarter YoY) −13.2% · Bottom 25%
Dividend yield (12 months) 0.1% · Bottom 25%
Balance sheet
Debt / equity 0.05× · Below median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 1.89× · Cheaper than median
P/S (12 months) 4.31× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 39
PAST (return on equity)0 · sector 15
HEALTH (low debt)97 · sector 95
DIVIDEND (yield)2 · sector 33

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥147.00 ¥164.66 +12% vs 300676
IQVIA Holdings IQV $271.83 $299.01 +10% vs 300676
Illumina, Inc ILMN $213.13 $234.44 +10% vs 300676
Thermo Fisher Scientific Inc TMO $694.76 $686.04 −1% vs 300676
Danaher Corporation DHR $230.25 $209.18 −9% vs 300676
IDEXX Laboratories, Inc IDXX $676.04 $496.48 −27% vs 300676
Mettler-Toledo International Inc MTD $1,722 $655.06 −62% vs 300676
Agilent Technologies, Inc A $174.76 $64.53 −63% vs 300676
Lonza Group LONN CHF 663.40 CHF 153.50 −77% vs 300676
Waters Corporation WAT $457.60 $91.26 −80% vs 300676

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

BGI Genomics Co Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "BGI Genomics Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/300676

Frequently asked questions

Is BGI Genomics Co Ltd (300676) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of ¥20.06 versus a price of ¥38.39, about 48% lower (overvalued).
What is the fair value of 300676?
Our model-based fair value for BGI Genomics Co Ltd is ¥20.06 (as of Nov 7, 2026), built from audited fundamentals. The current price: ¥38.39.
What is the quality score of 300676?
BGI Genomics Co Ltd has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BGI Genomics Co Ltd (300676)?
Our model-based price target is the fair value of ¥20.06 (as of Nov 7, 2026) from 2 valuation models. Cautious scenario ¥17.15, optimistic scenario ¥22.97. It is a calculation from audited fundamentals, not an analyst target.
What is the BGI Genomics Co Ltd stock forecast for 2026?
Our models put fair value at ¥20.06, about 48% lower versus a price of ¥38.39 (overvalued). Cautious scenario ¥17.15, optimistic scenario ¥22.97. The calculation is refreshed regularly with new filings.
What is the revenue of BGI Genomics Co Ltd (300676)?
BGI Genomics Co Ltd reported trailing-twelve-month revenue of about 3.7B CNY (latest available figure, as of Nov 7, 2026).
Does BGI Genomics Co Ltd pay a dividend?
BGI Genomics Co Ltd currently shows a dividend yield of 0.10% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of BGI Genomics Co Ltd (300676)?
BGI Genomics Co Ltd has a dividend yield of 0.1%.
What is the intrinsic value of BGI Genomics Co Ltd (300676)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BGI Genomics Co Ltd it is ¥20.06 per share (as of Nov 7, 2026), against a price of ¥38.39. It is the blended result of 2 valuation models in 2 families (Multiples, Asset-Based).
Is BGI Genomics Co Ltd stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 300676 trades above its calculated fair value: price ¥38.39, fair value ¥20.06, a gap of about −48% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300676?
No. The price is what the market pays today (¥38.39); the fair value is what the company's own numbers justify (¥20.06). For BGI Genomics Co Ltd the two are ¥18.33 per share apart. That gap is exactly why we show both numbers side by side.
How much is BGI Genomics Co Ltd worth?
The market values BGI Genomics Co Ltd at about 16.1B CNY (market capitalisation, as of Nov 7, 2026). Per share that is ¥38.39; our models calculate a fair value of ¥20.06 per share.
What do the bullish and bearish scenarios say about 300676?
Our models span a range for BGI Genomics Co Ltd: cautious scenario ¥17.15, base ¥20.06, optimistic ¥22.97 per share (as of Nov 7, 2026, price ¥38.39). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of BGI Genomics Co Ltd (300676)?
Balance-sheet figures for BGI Genomics Co Ltd (as of Nov 7, 2026): return on equity −6.3%, debt of 0.05 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is 300676 from its 52-week high?
BGI Genomics Co Ltd trades at ¥38.39, about 35% below its 52-week high of ¥59.25 and 17% above the low of ¥32.88 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥20.06 is for.
Which stocks are comparable to BGI Genomics Co Ltd?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BGI Genomics Co Ltd stock attractive at the current price?
The data as of Nov 7, 2026: price ¥38.39, calculated fair value ¥20.06 (−48%), Quality Score 48/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300676 calculated?
We run BGI Genomics Co Ltd through 2 models from 2 families: Multiples, Asset-Based. Every model gets the same audited fundamentals; the fair value of ¥20.06 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. BGI Genomics Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BGI Genomics Co Ltd (300676)?
The closing price on Nov 6, 2026 was ¥38.39. Our model-based fair value is ¥20.06, about 48% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BGI Genomics Co Ltd right now?
The price sits above even our optimistic bull case (¥22.97). The favourable scenario is already priced in. Weak quality (48/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Where does the earnings growth of BGI Genomics Co Ltd (300676) come from?
Earnings per share at BGI Genomics Co Ltd grew +6.7 % a year from 2013 to 2024. Broken into its drivers: revenue per share +12.3 %, EBIT margin −4.8 %, tax rate −0.1 %, residual (interest, one-offs) −0.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of BGI Genomics Co Ltd

How large is the market capitalisation of BGI Genomics Co Ltd (300676)?
The market capitalisation of BGI Genomics Co Ltd is 16.1B CNY (≈ $2.4B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BGI Genomics Co Ltd (300676)?
The price-to-sales ratio of BGI Genomics Co Ltd is 4.55 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BGI Genomics Co Ltd (300676)?
Earnings per share at BGI Genomics Co Ltd are ¥−1.38. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of BGI Genomics Co Ltd (300676)?
The dividend yield of BGI Genomics Co Ltd is 0.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of BGI Genomics Co Ltd (300676)?
The net margin of BGI Genomics Co Ltd is −14.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BGI Genomics Co Ltd (300676)?
The return on equity (ROE) of BGI Genomics Co Ltd is −6.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BGI Genomics Co Ltd (300676)?
On an EBIT basis the return on assets of BGI Genomics Co Ltd is 2.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BGI Genomics Co Ltd (300676)?
The operating margin of BGI Genomics Co Ltd is 3.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BGI Genomics Co Ltd (300676)?
Revenue at BGI Genomics Co Ltd is growing −13.2% versus a year earlier (3y avg −19.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at BGI Genomics Co Ltd (300676)?
Earnings per share at BGI Genomics Co Ltd are growing −2.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does BGI Genomics Co Ltd (300676) generate?
The free cash flow of BGI Genomics Co Ltd is −569M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does BGI Genomics Co Ltd (300676) hold?
BGI Genomics Co Ltd holds more cash than debt, 3.5B CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch BGI Genomics Co Ltd in the live analysis

One click puts BGI Genomics Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.